Ra Medical Systems (RMED) Reports Increased Enrollment in Pivotal Atherectomy Clinical Trial
- Wall Street ends higher, investors juggle Fed nerves with AI enthusiasm
- Apple in talks with Google to use generative AI in iPhones- Bloomberg
- World shares cheer China data, as central banks line up
- Oil prices climb 2% to 4-month high on lower Iraq, Saudi exports
- Meta Platforms is a new Top Pick at Mizuho, analyst sees upside to consensus
- After-hours movers: ANSYS, National CineMedia, and more
- Midday movers: Google, Pepsi rise; Boeing, Zillow fall
- Midday movers: Adobe, Zillow fall; Micron rises
- After-hours movers: Adobe Systems slumps; Rivian, Ulta Beauty gain
- Midday movers: Tesla, Nvidia fall premarket; Robinhood, Dollar General rise
Ra Medical Systems Provides Enrollment Update for its Pivotal Atherectomy Clinical Trial
April 20, 2021 6:05 AM EDT42 total subjects enrolled as of April 19, 2021
12 subjects enrolled since mid-March
CARLSBAD, Calif.--(BUSINESS WIRE)-- Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces an increase in... More